Northern Securities Inc. acted as the agent on this financing and received a cash commission of $20,000 representing 8% of the gross proceeds of the financing, a work fee of $5,000 and a non-assignable agent's warrant to acquire 250,000 common shares at a price of $0.10 per share until 5:00 p.m. (Toronto time) on the date that is 24 months following the date of listing the common shares on a recognized stock exchange. As a result of the financing, Primera Bioscience now has 4,000,000 shares issued and outstanding.

Primera Bioscience is engaged in early stage biomedical research. The Corporation currently has one project which is to collaborate with and provide $300,000 of funding for certain brain tumour and stem cell research being conducted by The Hospital for Sick Children in Toronto, Ontario. This research is more fully described in the prospectus of Primera Bioscience dated July 23, 2008 which is filed on www.sedar.com. This research is ongoing and further announcements will be made when results are available.

WARNING: This News Release includes certain "forward-looking statements". All statements other than statements of historical fact included in this release, including, without limitation, statements regarding research and the potential results thereof, and future plans and objectives of Primera Bioscience, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Primera Bioscience ' expectations are exploration risks detailed herein and from time to time in the filings made by Primera Bioscience with securities regulators.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.